Cell Medica will start producing WT1-TCR cell treatment for solid tumors which have been difficult to treat with traditional treatments, including mesothelioma and ovarian cancer. Mobile Medica is likely to commence a Phase 1/2 trial employing a Dominant WT1-TCR edition of the merchandise in late 2018.
WT1-TCR cell treatment involves taking a patient’s immune cells and changing them so that they mount a response against tumor cells using a protein known as Wilms’ tumor gene 1 (WT1). The WT1 protein is found in 75 percentage of mesotheliomas and in 93 percentage of ovarian serous carcinomas. TCRs are T-cell receptors, proteins which may single out specific objects, located in the surfaces of T-cells.
The treatment was initially developed for acute myeloid leukemia and myelodysplastic syndrome in University College London (UCL) and Imperial College London. A Phase 1 trial has been conducted in UCL and Imperial College London with financing from the U.K. charity Bloodwise.
CGT Catapult attracted WT1-TCR into a Stage 1/2 clinical trial and invented an improved production procedure. Now it has finished the treatment of eight patients with promising results, CGT Catapult is shifting the WT1-TCR cell treatment rights to Mobile Medica to keep development and deliver the product to regulatory acceptance.
Mobile Medica entered to some collaboration with UCL in 2016 to encourage a study team there at the evolution of new TCRs to be used in anti inflammatory treatment. Now, Mobile Medica has purchased Catapult Remedy TCR, a firm set up by Cell and Gene Therapy Catapult (CGT Catapult), UCL Business, and Imperial Innovations to create the WT1-TCR technology.
Mobile Medica will create the mobile therapy at CGT Catapult’s GMP manufacturing center in Stevenage, England.
“The purchase of this WT1-TCR cell treatment frees the investment that we made 2016 for exclusive rights to the Dominant TCR technologies,” Gregg Sando, CEO of Mobile Medica, stated in a press release.
“Our purpose is to demonstrate how we can improve any present TCR cell treatment together with the Dominant TCR technologies to make a more successful treatment for patients with solid tumors that otherwise have an extremely poor outlook,” he explained. “We’re also anticipating a significant collaboration with CGT Catapult to begin manufacturing in the Stevenage GMP centre where we’ll work collectively on scale-up plans for industrial production.”
The article Cell Medica to Manufacture WT1-TCR Therapy for Mesothelioma, Other Solid Tumors in 2018 appeared initially on The Asbestos Cancer Organization.